Farukh Khan, MD
Emergency Medicine · Elkins, WVNPI 1790722809
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,679 of the $2,314 with a category attached, or 72.6%. 17 manufacturers reported payments, led by AstraZeneca at 32.7% of the total. Among emergency medicine clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 85 payments — averaging $27.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$757
- Astellas Pharma US Inc$603
- Amgen$195
- Novo Nordisk$187
- GSK$118
- Abbott$98
- plus $355 from 11 others
What the payments were for
- Food & beverage$1,67973%
- Education$63527%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $757 |
| Astellas Pharma US Inc | 7 | $603 |
| Amgen | 7 | $195 |
| Novo Nordisk | 6 | $187 |
| GSK | 2 | $118 |
| Abbott | 6 | $98 |
| Amarin Pharma, Inc. | 5 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $78 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Merck | 2 | $26 |
| Vertex | 1 | $25 |
| Pfizer | 1 | $20 |
| Bayer | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| AbbVie | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$125
- FARXIGA$125
- TRELEGY ELLIPTA$101
How this compares
$2,314 in reported general payments places this provider in the 95th percentile of 367 emergency medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 138 | $170,788 |
| OzempicSemaglutide | 118 | $160,114 |
| EliquisApixaban | 81 | $109,733 |
| JardianceEmpagliflozin | 68 | $98,552 |
| FarxigaDapagliflozin Propanediol | 73 | $68,938 |
| MounjaroTirzepatide | 44 | $47,371 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $36,512 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $31,725 |
| KerendiaFinerenone | 26 | $28,209 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $20,291 |
| TrulicityDulaglutide | 17 | $20,144 |
| Icosapent Ethyl | 22 | $13,588 |
| VascepaIcosapent Ethyl | 15 | $13,463 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $11,124 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $8,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $187 | $330,901256 claims |
| PfizerEliquis | $20 | $109,73381 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $757 | $100,66398 claims |
| Lilly USA, LLCMounjaro, Trulicity | $12 | $67,51561 claims |
| GSKTrelegy Ellipta | $118 | $36,51230 claims |
| BayerKerendia | $20 | $28,20926 claims |
| AbbVieSynthroid | $13 | $1,75230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 367 emergency medicine providers in West Virginia.
Other emergency medicine in Elkins
- Joseph MinardiMorgantown$35K
- Khaled SaidPetersburg$21K
- Albeir MousaCharleston$12K
- Benjamin SilverbergMorgantown$7K
- Joseph PalumboGlen Dale$3K
- Matt LambertParkersburg$2K
- Christian BosquetWeirton$2K
- Jessica CarmichaelCharleston$2K
- Stanley MorrisSummersville$1K
- Nathan BerryFairmont$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.